{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=38", "query": { "condition": "Adenocarcinoma Lung", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 912, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T19:52:58.145Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04440943", "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "MSI-H Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Other Solid Tumors" ], "interventions": [ { "name": "CDX-527", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-08-04", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04440943" }, { "nct_id": "NCT01204476", "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrin-Producing Neuroendocrine Tumor", "Lung Carcinoid Tumor", "Metastatic Digestive System Neuroendocrine Tumor G1", "Pancreatic Glucagonoma", "Pancreatic Insulinoma", "Pancreatic Polypeptide Tumor", "Paraganglioma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Merkel Cell Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Somatostatin-Producing Neuroendocrine Tumor", "Stage III Merkel Cell Carcinoma", "Stage IV Merkel Cell Carcinoma", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-15", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204476" }, { "nct_id": "NCT06145750", "title": "Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Ability to order FirstLook™", "type": "DIAGNOSTIC_TEST" }, { "name": "Continuing Medical Education for Lung Cancer", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Delfi Diagnostics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 28, "start_date": "2023-10-31", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 3, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Durham, North Carolina", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06145750" }, { "nct_id": "NCT07090499", "title": "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors", "Bladder Cancer", "Urothelial Carcinoma", "Advanced Non-Small Cell Lung Cancer", "Carcinoma, Non Small Cell Lung", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Esophageal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "PF-08046876", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-20", "completion_date": "2029-07-08", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 21, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07090499" }, { "nct_id": "NCT05064150", "title": "Neuroendocrine Tumors - Patient Reported Outcomes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Tumors", "Gastroenteropancreatic Neuroendocrine Tumor", "Lung Neuroendocrine Neoplasm", "Neuroendocrine Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2539, "start_date": "2022-05-10", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 14, "location_summary": "Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 11 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064150" }, { "nct_id": "NCT01706432", "title": "Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Central Nervous System Metastases", "Invasive Ductal Breast Carcinoma", "Invasive Ductal Breast Carcinoma With Predominant Intraductal Component", "Invasive Lobular Breast Carcinoma", "Invasive Lobular Breast Carcinoma With Predominant in Situ Component", "Liver Metastases", "Lobular Breast Carcinoma in Situ", "Lung Metastases", "Male Breast Cancer", "Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate", "Mucinous Ductal Breast Carcinoma", "Papillary Ductal Breast Carcinoma", "Recurrent Breast Cancer", "Stage IV Breast Cancer", "Tubular Ductal Breast Carcinoma", "Tumors Metastatic to Brain" ], "interventions": [ { "name": "hyperfractionated radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "stereotactic radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2009-06-15", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 1, "location_summary": "North Chicago, Illinois", "locations": [ { "city": "North Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01706432" }, { "nct_id": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1756, "start_date": "2013-01-31", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 53, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772004" }, { "nct_id": "NCT05121948", "title": "A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Colo-rectal Cancer", "Non Small Cell Lung Cancer", "Transitional Cell Carcinoma of the Bladder", "Other Solid Tumors", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "HC-7366", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-02-23", "completion_date": "2024-03-01", "has_results": false, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 7, "location_summary": "La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05121948" }, { "nct_id": "NCT03633110", "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Urothelial Carcinoma", "Renal Cell Carcinoma" ], "interventions": [ { "name": "GEN-009 Adjuvanted Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-08-29", "completion_date": "2022-02-28", "has_results": false, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 11, "location_summary": "La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03633110" }, { "nct_id": "NCT03695835", "title": "A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Immunotherapeutic Agents", "type": "DRUG" }, { "name": "Ablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Gary Onik MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 27, "start_date": "2018-04-11", "completion_date": "2020-06-17", "has_results": false, "last_update_posted_date": "2020-07-22", "last_synced_at": "2026-10-16T19:52:58.145Z", "location_count": 1, "location_summary": "Fort Lauderdale, Florida", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03695835" } ] }